Land: Singapore
Sprog: engelsk
Kilde: HSA (Health Sciences Authority)
FENTANYL CITRATE 78.5MCG EQV TO FENTANYL BASE
ALLIANCE PHARM PTE. LTD.
N01AH01
INJECTION, SOLUTION
FENTANYL CITRATE 78.5MCG EQV TO FENTANYL BASE 50MCG
INTRAVENOUS, INTRAMUSCULAR
Prescription Only
MACARTHYS LABORATORIES LIMITED T\A MARTINDALE PHARMA
ACTIVE
2019-05-16
PRODUCT INFORMATION MARTINDALE PHARMA FENTANYL SOLUTION FOR INJECTION 50 MICROGRAMS/ML 1 NAME OF THE MEDICINAL PRODUCT Fentanyl 50 micrograms/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Fentanyl citrate 78.5 micrograms equivalent to 50 micrograms per ml fentanyl base. Excipient(s) with known effect: Sodium 3.5 mg/ml. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Clear, colourless, sterile solution for Injection 4 PHARMACOLOGICAL PROPERTIES 4.1 PHARMACODYNAMIC PROPERTIES Pharmacotherapeutic group: Anaesthetic general, opioid anaesthetic. ATC code: N01AH01 Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single IV dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical anaesthesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals. 4.2 PHARMACOKINETIC PROPERTIES Some pharmacokinetic parameters for fentanyl are as follows: Urinary excretion = 8% Bound in plasma = 80% Clearance (ml/min/kg) = 13±2 Volume of distribution (litres/kg) = 4.0±0.4 Estimates of terminal half-life range from 141 to 853 minutes. Renal impairment Data obtained from a study administering IV fentanyl in patients undergoing renal transplantation suggest that the clearance of fentanyl may be reduced in this patient population. If patients with renal impairment receive fentanyl, they should be observed carefully for signs of fentanyl toxicity and the dose reduced if necessary (see section 4.2 Posology and method of administration) Læs hele dokumentet